UBE2C and ovarian carcinoma: Ubiquitination and deubiquitination are known to be modulated during cancer progression (Sun et al., 2020), and high UBE2C expression portends poor survival in various cancers including node-positive breast cancer (Loussouarn et al., 2009) and ovarian carcinomas (Berlingieri et al., 2007).